MedTrace Logo

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

NCT07564232 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-04

No results posted yet for this study

Summary

There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC.

The goal of Part 2 is to learn if the recommended dose of LNK001 found in Part 1 can help to control the disease.

Conditions

Interventions

DRUG

Cyclophosphamide

Given by IV

DRUG

Fludarabine

Given by IV

DRUG

LNK001

Given by infusion

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Samer A Srour, MBBCH · UT MD Anderson

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2031-06-06
Completion
2033-06-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07564232 on ClinicalTrials.gov